- Home
- SNT vs STTK Comparison
SNT vs STTK Comparison
Compare SNT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- STTK
- Stock Information
- Founded
- SNT 1965
- STTK 2016
- Country
- SNT Canada
- STTK United States
- Employees
- SNT N/A
- STTK N/A
- Industry
- SNT Telecommunications Equipment
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- STTK Health Care
- Exchange
- SNT Nasdaq
- STTK Nasdaq
- Market Cap
- SNT 95.2M
- STTK 112.6M
- IPO Year
- SNT 1993
- STTK 2020
- Fundamental
- Price
- SNT $4.93
- STTK $1.98
- Analyst Decision
- SNT
- STTK Hold
- Analyst Count
- SNT 0
- STTK 5
- Target Price
- SNT N/A
- STTK $3.00
- AVG Volume (30 Days)
- SNT 64.1K
- STTK 384.9K
- Earning Date
- SNT 11-11-2025
- STTK 11-13-2025
- Dividend Yield
- SNT N/A
- STTK N/A
- EPS Growth
- SNT N/A
- STTK N/A
- EPS
- SNT 0.22
- STTK N/A
- Revenue
- SNT $38,038,000.00
- STTK $2,997,000.00
- Revenue This Year
- SNT N/A
- STTK N/A
- Revenue Next Year
- SNT N/A
- STTK N/A
- P/E Ratio
- SNT $22.09
- STTK N/A
- Revenue Growth
- SNT 12.79
- STTK N/A
- 52 Week Low
- SNT $1.40
- STTK $0.69
- 52 Week High
- SNT $5.34
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- SNT 56.41
- STTK 50.13
- Support Level
- SNT $4.33
- STTK $1.78
- Resistance Level
- SNT $5.34
- STTK $2.08
- Average True Range (ATR)
- SNT 0.32
- STTK 0.19
- MACD
- SNT 0.03
- STTK -0.03
- Stochastic Oscillator
- SNT 62.85
- STTK 41.07
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.